These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

777 related items for PubMed ID: 17291758

  • 1. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.
    Steegmaier M, Hoffmann M, Baum A, Lénárt P, Petronczki M, Krssák M, Gürtler U, Garin-Chesa P, Lieb S, Quant J, Grauert M, Adolf GR, Kraut N, Peters JM, Rettig WJ.
    Curr Biol; 2007 Feb 20; 17(4):316-22. PubMed ID: 17291758
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
    Liu X, Choy E, Harmon D, Yang S, Yang C, Mankin H, Hornicek FJ, Duan Z.
    Anticancer Drugs; 2011 Jun 20; 22(5):444-53. PubMed ID: 21399492
    [Abstract] [Full Text] [Related]

  • 3. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1.
    Lénárt P, Petronczki M, Steegmaier M, Di Fiore B, Lipp JJ, Hoffmann M, Rettig WJ, Kraut N, Peters JM.
    Curr Biol; 2007 Feb 20; 17(4):304-15. PubMed ID: 17291761
    [Abstract] [Full Text] [Related]

  • 4. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity.
    Rudolph D, Steegmaier M, Hoffmann M, Grauert M, Baum A, Quant J, Haslinger C, Garin-Chesa P, Adolf GR.
    Clin Cancer Res; 2009 May 01; 15(9):3094-102. PubMed ID: 19383823
    [Abstract] [Full Text] [Related]

  • 5. Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma.
    Nappi TC, Salerno P, Zitzelsberger H, Carlomagno F, Salvatore G, Santoro M.
    Cancer Res; 2009 Mar 01; 69(5):1916-23. PubMed ID: 19223553
    [Abstract] [Full Text] [Related]

  • 6. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis.
    Gilmartin AG, Bleam MR, Richter MC, Erskine SG, Kruger RG, Madden L, Hassler DF, Smith GK, Gontarek RR, Courtney MP, Sutton D, Diamond MA, Jackson JR, Laquerre SG.
    Cancer Res; 2009 Sep 01; 69(17):6969-77. PubMed ID: 19690138
    [Abstract] [Full Text] [Related]

  • 7. The polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma.
    Stewart HJ, Kishikova L, Powell FL, Wheatley SP, Chevassut TJ.
    Exp Hematol; 2011 Mar 01; 39(3):330-8. PubMed ID: 21184800
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
    Cholewa BD, Ndiaye MA, Huang W, Liu X, Ahmad N.
    Cancer Lett; 2017 Jan 28; 385():179-187. PubMed ID: 27793694
    [Abstract] [Full Text] [Related]

  • 15. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.
    Lee C, Fotovati A, Triscott J, Chen J, Venugopal C, Singhal A, Dunham C, Kerr JM, Verreault M, Yip S, Wakimoto H, Jones C, Jayanthan A, Narendran A, Singh SK, Dunn SE.
    Stem Cells; 2012 Jun 28; 30(6):1064-75. PubMed ID: 22415968
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
    Ding Y, Huang D, Zhang Z, Smith J, Petillo D, Looyenga BD, Feenstra K, Mackeigan JP, Furge KA, Teh BT.
    Cancer Res; 2011 Aug 01; 71(15):5225-34. PubMed ID: 21642374
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.